ondansetron has been researched along with Multiple Myeloma in 4 studies
Ondansetron: A competitive serotonin type 3 receptor antagonist. It is effective in the treatment of nausea and vomiting caused by cytotoxic chemotherapy drugs, including cisplatin, and has reported anxiolytic and neuroleptic properties.
Multiple Myeloma: A malignancy of mature PLASMA CELLS engaging in monoclonal immunoglobulin production. It is characterized by hyperglobulinemia, excess Bence-Jones proteins (free monoclonal IMMUNOGLOBULIN LIGHT CHAINS) in the urine, skeletal destruction, bone pain, and fractures. Other features include ANEMIA; HYPERCALCEMIA; and RENAL INSUFFICIENCY.
| Excerpt | Relevance | Reference |
|---|---|---|
| "Forty-one patients with multiple myeloma were treated with a novel stem cell mobilisation regimen." | 6.70 | Dexamethasone, paclitaxel, etoposide, cyclophosphamide (d-TEC) and G-CSF for stem cell mobilisation in multiple myeloma. ( Bilgrami, S; Bona, RD; Clive, J; Edwards, RL; Fox, J; Furlong, F; Li, Z; Naqvi, B; Shaikh, A; Tutschka, PJ, 2001) |
| "Forty-one patients with multiple myeloma were treated with a novel stem cell mobilisation regimen." | 2.70 | Dexamethasone, paclitaxel, etoposide, cyclophosphamide (d-TEC) and G-CSF for stem cell mobilisation in multiple myeloma. ( Bilgrami, S; Bona, RD; Clive, J; Edwards, RL; Fox, J; Furlong, F; Li, Z; Naqvi, B; Shaikh, A; Tutschka, PJ, 2001) |
| "Ondansetron is a highly effective non-sedative antiemetic that justifies further assessment in combination with other antiemetics in patients receiving cytotoxic drugs associated with the production of severe nausea and vomiting." | 1.28 | Ondansetron--a new safe and effective antiemetic in patients receiving high-dose melphalan. ( Butcher, ME; Gore, ME; McElwain, TJ; Selby, PJ; Viner, CV; Wootton, CM; Zulian, GB, 1990) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 2 (50.00) | 18.2507 |
| 2000's | 2 (50.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Mathews, HG | 1 |
| Tancil, CG | 1 |
| Lacerda, JF | 1 |
| Martins, C | 1 |
| Carmo, JA | 1 |
| Lourenço, MF | 1 |
| Araújo Pereira, ME | 1 |
| Rodrigues, A | 1 |
| Juncal, C | 1 |
| Lacerda, JM | 1 |
| Bilgrami, S | 1 |
| Bona, RD | 1 |
| Edwards, RL | 1 |
| Li, Z | 1 |
| Naqvi, B | 1 |
| Shaikh, A | 1 |
| Furlong, F | 1 |
| Fox, J | 1 |
| Clive, J | 1 |
| Tutschka, PJ | 1 |
| Viner, CV | 1 |
| Selby, PJ | 1 |
| Zulian, GB | 1 |
| Gore, ME | 1 |
| Butcher, ME | 1 |
| Wootton, CM | 1 |
| McElwain, TJ | 1 |
2 trials available for ondansetron and Multiple Myeloma
| Article | Year |
|---|---|
Randomized trial of ondansetron, granisetron, and tropisetron in the prevention of acute nausea and vomiting.
Topics: Adult; Antiemetics; Antineoplastic Combined Chemotherapy Protocols; Combined Modality Therapy; Femal | 2000 |
Dexamethasone, paclitaxel, etoposide, cyclophosphamide (d-TEC) and G-CSF for stem cell mobilisation in multiple myeloma.
Topics: Adult; Aged; Antiemetics; Antigens, CD; Antigens, CD34; Antineoplastic Combined Chemotherapy Protoco | 2001 |
2 other studies available for ondansetron and Multiple Myeloma
| Article | Year |
|---|---|
Extrapyramidal reaction caused by ondansetron.
Topics: Aged; Antiemetics; Antineoplastic Agents; Basal Ganglia Diseases; Humans; Male; Multiple Myeloma; Na | 1996 |
Ondansetron--a new safe and effective antiemetic in patients receiving high-dose melphalan.
Topics: Administration, Oral; Antiemetics; Drug Administration Schedule; Drug Evaluation; Female; Humans; Im | 1990 |